Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Erratum

Erratum to ‘Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study’ [Clin Mol Hepatol 2024;30:487-499]

Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park

Clin Mol Hepatol. 2025;31(3):1105-1106. Published online July 1, 2025

DOI: https://doi.org/10.3350/cmh.2024.0145e
Corrects: Clin Mol Hepatol 2024;30(3):487

View: 383 Download: 7

Erratum to ‘Systemic therapy in advanced hepatocellular carcinoma’ [Clin Mol Hepatol 2023;29:516-519]

Joseph C. Ahn, Nguyen H. Tran, Ju Dong Yang

Clin Mol Hepatol. 2025;31(3):1103-1104. Published online July 1, 2025

DOI: https://doi.org/10.3350/cmh.2023.0051e
Corrects: Clin Mol Hepatol 2023;29(2):516

View: 367 Download: 5

Special Review

Liver disease trends in the Asia-Pacific region for the next 50 years

Shuichiro Shiina, Javkhlan Maikhuu, Qing Deng, Terguunbileg Batsaikhan, Lariza Marie Canseco, Maki Tobari, Hitoshi Maruyama, Hiroaki Nagamatsu, Diana Alcantara-Payawal, Rino Gani, Yi-Hsiang Huang, Tawesak Tanwandee, Giovanni Galati, Yoon Jun Kim

Clin Mol Hepatol. 2025;31(3):671-684. Published online March 4, 2025

DOI: https://doi.org/10.3350/cmh.2025.0043

View: 1598 Download: 132 Crossref: 1

Research Letter

Mendelian randomization does not support the effects of G CSF on decompensated liver disease

Liling Li, Hui Wang, Hong Wang, Jinchang Huang

Clin Mol Hepatol. 2025;31(3):e254-e258. Published online March 4, 2025

DOI: https://doi.org/10.3350/cmh.2025.0172

View: 795 Download: 45

Lipidomic analysis of alcohol use disorder patients revealed the biomarkers for alcohol-related liver disease susceptibility

Dongyao Wang, Hongwei Zhang, Yuxiao Tang

Clin Mol Hepatol. 2025;31(3):e259-e262. Published online April 2, 2025

DOI: https://doi.org/10.3350/cmh.2025.0227

View: 792 Download: 66 Crossref: 1

Hydrophilic and lipophilic statin and clinical outcomes in individuals with alcohol-associated liver disease

Pojsakorn Danpanichkul, Donghee Kim, Benjamin Nah, Karn Wijarnpreecha, Suthat Liangpunsakul

Clin Mol Hepatol. 2025;31(3):e273-e276. Published online May 27, 2025

DOI: https://doi.org/10.3350/cmh.2025.0474

View: 462 Download: 18

Non-infectivity of hepatitis B virus under nucleoside analog therapy revealed through auxiliary partial orthotopic liver transplantation

Xiaojie Chen, Guiwen Guan, Lin Wei, Jidong Jia, Xiangmei Chen, Fengmin Lu, Zhijun Zhu

Clin Mol Hepatol. 2025;31(3):e263-e267. Published online May 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0393

View: 567 Download: 44

Contemporary burden of mortality from chronic liver disease by sex and race/ethnicity in the United States

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(3):e268-e272. Published online May 8, 2025

DOI: https://doi.org/10.3350/cmh.2025.0384

View: 563 Download: 36 Crossref: 1

Rising drug overdose deaths in chronic liver disease in the United States, 2015–2023

Donghee Kim, Brittany B Dennis, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(3):e277-e280. Published online May 27, 2025

DOI: https://doi.org/10.3350/cmh.2025.0548

View: 477 Download: 22

Erratum

Erratum to ‘Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial’ [Clin Mol Hepatol 2024;30:807-823]

Sun Young Yim, Sung Hwan Lee, Seung-Woo Baek, Bohwa Sohn, Yun Seong Jeong, Sang-Hee Kang, Kena Park, Hyewon Park, Sunyoung S. Lee, Ahmed O. Kaseb, Young Nyun Park, Sun-Hee Leem, Michael A. Curran, Ji Hoon Kim, Ju-Seog Lee

Clin Mol Hepatol. 2025;31(2):669-670. Published online February 27, 2025

DOI: https://doi.org/10.3350/cmh.2024.0333e
Corrects: Clin Mol Hepatol 2024;30(4):807

View: 1187 Download: 46

Correspondence

Correspondence to editorial on “Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306)”

Chuan Liu, Ling Yang, Hong You, Gao-Jun Teng, Xiaolong Qi

Clin Mol Hepatol. 2025;31(2):e155-e157. Published online August 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.0723

View: 1305 Download: 50

Correspondence to letter to the editor on “Contemporary awareness of viral hepatitis between 2012 and 2022 among Korean adults”

Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong

Clin Mol Hepatol. 2025;31(2):e149-e151. Published online November 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0944

View: 1089 Download: 20

Correspondence to editorial on “Safety and efficacy of HK-660S in patients with primary sclerosing cholangitis: A randomized double-blind phase 2a trial”

Woo Hyun Paik, Do Hyun Park

Clin Mol Hepatol. 2025;31(2):e158-e160. Published online November 11, 2024

DOI: https://doi.org/10.3350/cmh.2024.0989

View: 1091 Download: 38

HCV self-testing: Bridging screening gaps and ensuring cost-effectiveness for both high-risk and universal populations: Correspondence to editorial on “Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness”

Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn

Clin Mol Hepatol. 2025;31(2):e163-e165. Published online November 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.1057

View: 998 Download: 37

Expanding treatment eligibility for chronic hepatitis B: Balancing benefits, limitations, and healthcare access: Correspondence to editorial on “Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial”

Yao-Chun Hsu, Chi-Yi Chen, Jaw-Town Lin

Clin Mol Hepatol. 2025;31(2):e169-e172. Published online December 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.1138

View: 978 Download: 26

Age serves as the silent architect of FIB-4’s precision in unveiling advanced hepatic fibrosis in MASLD with T2DM: Correspondence to letter to the editor on “Diagnostic accuracy of the fibrosis-4 index for advanced liver fibrosis in nonalcoholic fatty liver disease with type 2 diabetes: a systematic review and meta-analysis”

Ji Won Han, Dae Won Jun

Clin Mol Hepatol. 2025;31(2):e152-e154. Published online December 30, 2024

DOI: https://doi.org/10.3350/cmh.2024.1160

View: 1222 Download: 34

Correspondence to editorial on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”

Yang Liu, Fan Peng, Siyuan Wang, Jinliang Xing

Clin Mol Hepatol. 2025;31(2):e166-e168. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1185

View: 938 Download: 32 Web of Science: 1 Crossref: 1

Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2025;31(2):e208-e209. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1171

View: 1294 Download: 26

Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”

Seogsong Jeong, Won Kim, Sang Min Park

Clin Mol Hepatol. 2025;31(2):e210-e211. Published online January 6, 2025

DOI: https://doi.org/10.3350/cmh.2024.1175

View: 1287 Download: 27

Correspondence to editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Nicholas A. Rouillard, Linda Henry, Mindie H. Nguyen

Clin Mol Hepatol. 2025;31(2):e173-e175. Published online January 9, 2025

DOI: https://doi.org/10.3350/cmh.2025.0001

View: 971 Download: 30 Web of Science: 1 Crossref: 1

Reply to Correspondence

Reply to correspondence on “Aberrant fragmentomic features of circulating cell-free mitochondrial DNA enable early detection and prognosis prediction of hepatocellular carcinoma”

Hyuk Soo Eun

Clin Mol Hepatol. 2025;31(2):e215-e217. Published online January 16, 2025

DOI: https://doi.org/10.3350/cmh.2025.0035

View: 993 Download: 22

Correspondence

Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen

Clin Mol Hepatol. 2025;31(2):e186-e188. Published online January 24, 2025

DOI: https://doi.org/10.3350/cmh.2025.0079

View: 876 Download: 37 Web of Science: 1 Crossref: 1

Reply to Correspondence

Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):e218-e220. Published online February 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0070

View: 902 Download: 29

Correspondence

Correspondence to editorial on “Targeting TM4SF1 promotes tumor senescence enhancing CD8+ T cell cytotoxic function in hepatocellular carcinoma”

Weifeng Zeng, Furong Liu, Yachong Liu, Zhanguo Zhang

Clin Mol Hepatol. 2025;31(2):e197-e199. Published online February 5, 2025

DOI: https://doi.org/10.3350/cmh.2025.0085

View: 959 Download: 31

TIPS insertion and systemic inflammation: Is it ever too late to lower portal pressure? Correspondence to editorial on “Insertion of a transjugular intrahepatic portosystemic shunt leads to sustained reversal of systemic inflammation in patients with decompensated liver cirrhosis”

Anja Tiede, Benjamin Maasoumy

Clin Mol Hepatol. 2025;31(2):e176-e179. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0135

View: 957 Download: 21 Crossref: 1

Correspondence to letter to the editor on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Soon Kyu Lee, Jong Young Choi

Clin Mol Hepatol. 2025;31(2):e212-e214. Published online February 10, 2025

DOI: https://doi.org/10.3350/cmh.2025.0100

View: 850 Download: 22

GOLM1 and bile acid synthesis: Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen

Clin Mol Hepatol. 2025;31(2):e189-e191. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0120

View: 881 Download: 30 Crossref: 1

Correspondence to editorial on “Optimal tacrolimus levels for reducing CKD risk and the impact of intrapatient variability on CKD and ESRD development following liver transplantation”

Soon Kyu Lee, Jong Young Choi

Clin Mol Hepatol. 2025;31(2):e161-e162. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0121

View: 840 Download: 30

Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”

Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Rohit Loomba, Aijaz Ahmed

Clin Mol Hepatol. 2025;31(2):e180-e182. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0125

View: 885 Download: 24

Reply to Correspondence

Reply to correspondence 1 on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

Yoon-su Ha, Won Kim, Seung-Jin Kim

Clin Mol Hepatol. 2025;31(2):e226-e227. Published online February 13, 2025

DOI: https://doi.org/10.3350/cmh.2025.0128

View: 1165 Download: 31

Viewed By 12753	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7683	Radiogenomics of intrahepatic cholangiocarcinoma predicts immunochemotherapy response and identifies therapeutic target
Viewed By 7187	MAFLD: How is it different from NAFLD?
Viewed By 5740	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 5681	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Cited By 369	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 354	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 232	MAFLD: How is it different from NAFLD?
Cited By 122	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 116	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Others